Silence Therapeutics (SLN) Expected to Announce Quarterly Earnings on Thursday

Silence Therapeutics (NASDAQ:SLN) is anticipated to announce its earnings results before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter.

Silence Therapeutics Stock Performance

Shares of SLN stock opened at $5.00 on Friday. The company has a market cap of $147.55 million, a price-to-earnings ratio of -3.18 and a beta of 1.05. The stock has a 50 day simple moving average of $5.85 and a 200-day simple moving average of $12.32. Silence Therapeutics has a 12-month low of $4.06 and a 12-month high of $27.72.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on SLN. BMO Capital Markets reaffirmed an “outperform” rating on shares of Silence Therapeutics in a research note on Monday, December 2nd. The Goldman Sachs Group began coverage on Silence Therapeutics in a research note on Tuesday, February 11th. They issued a “sell” rating and a $6.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $75.00 price objective on shares of Silence Therapeutics in a research note on Wednesday, January 29th. William Blair reaffirmed an “outperform” rating on shares of Silence Therapeutics in a research note on Tuesday, November 19th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $55.00 price objective on shares of Silence Therapeutics in a research note on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, Silence Therapeutics has an average rating of “Moderate Buy” and an average target price of $45.00.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.